华讯
华讯
≡ 导航
网站首页
请拖入内容到容器
华讯
关于我们
请拖入内容到容器
华讯
2020-China's Biomedicine Ushers in the Upsurge of Listing
Affected by the COVID-19, global IPO activity slows down in 2020. But this year is a glorious year for China's biomedical companies. Since 2018, the Hong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange has been officially opened for trading. It has brought new vitality to China's capital market and the development of China's technology.. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list. According to incomplete statistics, as of Nov 20, at least 13 Chinese biopharmaceutical companies have been listed on the HKEx and 10 companies have been listed on the STAR Market. See the table below for details:   S/N Company name Stock Exchange Capital Raised Business area 1 Akeso,Inc HKEx Over $300 million Tumour、Autoimmune disease 2 Innocare HKEx About HK$2.093 billion Cancer、Autoimmune disease 3 Kintor Pharmaceutical Limited HKEx About $240 million Prostate Cancer、Breast Cancer Liver cancer、Baldness 4 Zai Lab Limited HKEx HK$5.73 billion Tumour、Autoimmune disease 5 Immunotech Biopharm Ltd HKEx HK$1.0241 billion T-Cell Immunotherapy 6 Ocumension Therapeutics HKEx HK$1.553 billion Ophthalmology 7   Hepalink HKEx HK$3.8 billion Heparin、Tumour 8 Jhbp (Cy) Holdings Limited HKEx ----- Tumour、Autoimmune disease 9 Everest Medicines Limited HKEx ----- Tumour、Autoimmune disease Cardiorenal diseases Infectious disease 10 Simcere Pharmaceutical Group Limited HKEx -----   Tumour、Central nervous system diseases、Autoimmune disease 11 Jw (Cayman) Therapeutics Co. Ltd HKEx ----- CAR-T 12 Remegen Co. Ltd. HKEx ----- Autoimmune disease、Tumour Ophthalmology 13 Antengene Corporation Limited HKEx ----- Tumour 14 Zelgen STAR Market About ¥2.026 billion Tumour、Hematopathy Hepatobiliary disease 15 Bio-Thera Solutions, Ltd STAR Market About ¥2.0 billion Tumour、Autoimmune disease 16 Sinocelltech Grou Limited STAR Market About ¥1.282 billion Monoclonal Antibody Recombination Protein、Vaccine 17 HitGen Inc. STAR Market About ¥830 million The lead drug 18 Cansino Biologics Inc. STAR Market About ¥5.2 billion Vaccine 19 Sunshine Guojian Pharmaceutical(shanghai) Co. Ltd. STAR Market ¥3.183 billion Antibody 20 Jiangsu Aidea Pharmaceutical Co.,ltd STAR Market ¥839.4 million Antidote、Tumour 21 Junshi BiosciencesCo., Ltd. STAR Market About ¥2.7 billion Tumour、Chronic disease Autoimmune disease 22 Easton BioPharmaceuticals Co.,Ltd STAR Market ¥1.335 billion Combination of generic drug development 23 Frontier Biotechnologies Inc STAR Market ¥1.845 billion AIDS antiviral treatment.  Pain therapy In addition to the companies listed in the above table, other biopharmaceutical companies such as Beijing Science Sun Pharmaceutical Co.,LTD、Changchun BCHT Biotechnology Co and other companies have also submitted IPO applications to the HKEx and the STAR Market
Details 白箭头 黑箭头
3D Medicines obtains exclusive development and commercialization authorization for new anti-cancer drugs in Greater China
Shanghai, China, November 11, 2020, 3D Medicines announced that it has reached a cooperation with Aravive. 3D Medicines will obtain the exclusive authorization for the clinical development and commercialization of Aravive's new drug AVB-500 in the oncology field of Greater China, and participate in the global clinical trial of AVB-500. Aravive will receive a $12 million contract and will be eligible for development and commercial milestone payments of up to $207 million. In addition, 3 will also pay Aravive a segmented sales commission based on AVB-500's annual net sales in Greater China. AVB-500, as a specific, high-affinity Fc fusion protein, is a new type of GAS6-AXL signaling pathway inhibitor. The GAS6-AXL signaling pathway is one of the important breakthroughs in the current tumor treatment field, with extremely high clinical value and huge market space. It has been confirmed in pre-clinical studies that AVB-500 can neutralize its activity by binding to GAS6, thereby selectively inhibiting the signaling pathway. At present, the clinical research of the drug is still in progress, and it has obtained fast track qualification granted by the US FDA for platinum-resistant recurrent ovarian cancer indications. In addition, AVB-500 was generally well tolerated, with no dose-limiting toxicity or unexpected safety signals. Aravive has successfully completed the Phase 1b trial of AVB-500 in platinum-resistant ovarian cancer and will enter the Phase III registration clinical study. Aravive also plans to initiate a Phase 1b/2 clinical trial of AVB-500 in clear cell renal cell carcinoma later in 2020. The product line of 3D Medicines includes differentiated biomacromolecules and small molecule anticancer drugs, and has an excellent team with international new drug development, registration and commercialization. 3D Medicines CEO Dr. Zhaolong Gong said: “As an innovative drug that can target a variety of tumors, AVB-500, combined with existing standard treatments or the company’s upcoming new drug Envafolimab, is expected to provide more convenient and more convenient Effective treatment options. We will work closely with Aravive to rapidly advance the development and commercialization of AVB-500, and bring this innovative drug with great therapeutic potential to Chinese cancer patients as soon as possible."
Details 白箭头 黑箭头
保守派大法官巴雷特就任美国最高法院,她是如何看待美国热点知识产权问题?
10月26日,保守派阵营的虔诚天主教徒巴雷特(Amy Coney Barrett),以52:48的得票获得美国参议院确认,并在美国总统特朗普的见证下,宣誓就任美国最高法院大法官。事实上从正式提名开始,大法官巴雷特始终饱受争议和批评。大法官巴雷特的任命意味着最高法院仅剩下3位自由派大法官,当晚的投票凸显出两党的巨大分歧,民主党45名参议员及2名独立参议员全部投票反对,共和党有52名参议员同意。这种争议包含对最高法院进一步保守化的担忧,现年48岁的大法官巴雷特,在拥有枪支、移民、女性堕胎等问题上持保守态度。巴雷特成为大法官后,保守派和自由派的人数变为6 : 3,这将对美国法院的保守主义带来较大的影响,大法官巴雷特对美国热点知识产权问题又是如何看待的呢? 美国参议院知识产权小组委员会主席汤姆,于10月16日在国会就热点知识产权问题与大法官巴雷特进行了会谈,双方主要讨论了专利资格和著作权法。参议员汤姆提问,对最高法院关于专利资格的裁决有何看法以及最高法院是否应当充分解释他们做出的判决。大法官巴雷特拒绝评论具体的案件,她表示最高法院包括她本人都在努力给出明确的意见,以便能为下级法院及社会公众做出良好的指导,清楚地解释判决是一种美德。 对于著作权法的问题,参议员汤姆提出,当今社会环境发生了很多变化,最高法院花了一个多世纪的时间来解释著作权法是否涵盖如相机、钢琴播放器、移动图像、互联网等新技术领域,最高法院还是国会更适合回答这些问题?大法官巴雷特认为这些问题更像是一个政策问题,所以似乎最好由立法机关来解决。应当由民主选举产生的机构,而不是法院,来制定的政策。 美国版著作权法的落后性是无法争辩的,国会必须采取行动。从谈话中可以看出,巴雷特法官并不持有著作权激进主义理论。她认为宪法所规定的政策问题最好由国会来解决。对于专利资格的问题,巴雷特法官表明法院愿意提供明确的意见给下级法院及公众。作为保守派大法官,巴雷特法官无疑对美国知识产权司法保护环境有着举足轻重的影响,这将在后续的案例中得以呈现。  
Details 白箭头 黑箭头
最新消息
请拖入内容到容器
重要服务
请拖入内容到容器
华讯
二维码
二维码

地址:江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

版权所有 © 南京华讯知识产权顾问有限公司      备案号:苏ICP备15002104号-1      网站建设:中企动力  南京      

联系我们
请拖入内容到容器
网站首页
关于我们
最新消息
重要服务
联系我们